ml8b00508_si_001.pdf (489.54 kB)
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis
journal contribution
posted on 2019-02-12, 22:14 authored by Steven H. Spergel, Michael E. Mertzman, James Kempson, Junqing Guo, Sylwia Stachura, Lauren Haque, Jonathan S. Lippy, Rosemary F. Zhang, Michael Galella, Sidney Pitt, Guoxiang Shen, Aberra Fura, Kathleen Gillooly, Kim W. McIntyre, Vicky Tang, John Tokarski, John S. Sack, Javed Khan, Percy H. Carter, Joel C. Barrish, Steven G. Nadler, Luisa M. Salter-Cid, Gary L. Schieven, Stephen T. Wrobleski, William J. PittsThe
four members of the Janus family of nonreceptor tyrosine kinases
play a significant role in immune function. The JAK family kinase
inhibitor, tofacitinib 1, has been approved in the United
States for use in rheumatoid arthritis (RA) patients. A number of
JAK inhibitors with a variety of JAK family selectivity profiles are
currently in clinical trials. Our goal was to identify inhibitors
that were functionally selective for JAK1 and JAK3. Compound 22 was prepared with the desired functional selectivity profile,
but it suffered from poor absorption related to physical properties.
Use of the phosphate prodrug 32 enabled progression to
a murine collagen induced arthritis (CIA) model. The demonstration
of a robust efficacy in the CIA model suggests that use of phosphate
prodrugs may resolve issues with progressing this chemotype for the
treatment of autoimmune diseases such as RA.